The infectivity-enhanced COX-2 CRAd is a potentially promising therapeutic agent for the treatment of mCRPC/NEPC, and the standard therapeutic strategy combined with this virus may provide better disease control and improvement of prognosis in such advanced PC patients with very few alternative therapies. Here, PTGS2 is linked to pachyonychia congenita.